Generic drug of the therapeutic class: Anesthesia, resuscitation, analgesics
active ingredients: Atropine sulfate
Box of 10 pre-filled syringes of 5 ml
· Preoperative treatment: Prevention of vaginal reactions (arrhythmia, bradycardia) associated with tracheal intubation and surgical manipulation.
· Cardiopulmonary resuscitation: treatment of sinus bradycardias and atrioventricular blocks.
· In combination with neostigmine: limitation of the muscarinic effects of neostigmine used after surgery for the neutralization of nondepolarizing muscle relaxants.
· Specific antidote in case of overdose of anticholinesterase, acute intoxication by organophosphorus (insecticides, nerve gas used as a chemical weapon, carbamates) or muscarinic mushrooms.
Dosage ATROPINE SULFATE AGUETTANT 1 mg / 5 mL Solution for injection Box of 10 5 ml pre-filled syringes
Atropine sulfate Aguettant 1 mg / 5 mL solution for injection in a pre-filled syringe should be administered under medical supervision.
Preoperative treatment (IV and exceptionally IM):
· Adults: 0.3 to 0.6 mg IV just before induction of anesthesia or 0.3 to 0.6 mg IM, 30 to 60 minutes before induction of anesthesia.
o Sinus bradycardia: 0.5 mg IV, every 2 to 5 minutes until the desired heart rate is reached.
o Atrioventricular block: 0.5 mg IV, every 3 to 5 minutes (maximum 3 mg).
In combination with neostigmine to limit its muscarinic effects:
· Adults: 0.6 to 1.2 mg IV
Antidote of organophosphorus compounds (pesticides, neurotoxic gases):
· Adults: 2 mg IV or IM, every 5 to 10 minutes.
Repeat the dose until muscarinic signs and symptoms disappear or signs of atropinisation appear (tachycardia, mydriasis).
Antidote of cholinesterase inhibitors and in case of intoxication by fungi:
· Adults: 0.6 to 1 mg IV or IM every 2 hours.
Repeat the dose until muscarinic signs and symptoms have disappeared or signs of atropinisation appear (tachycardia, mydriasis).
Administration mode :
Atropine is administered by intravenous injection or intramuscular injection.
The pre-filled syringe is not suitable for administration to a pediatric population; the graduation does not allow precise measurement.
· Hypersensitivity to the active substance or to any of the excipients,
· Angle closure glaucoma
· Risk of urinary retention due to prostate or urethral disease,
· Myasthenia gravis unless administered in combination with anticholinesterase,
· Breastfeeding (see section on Pregnancy and lactation )
· Achalasia of the esophagus.
Adverse effects Atropine Sulfate Aguettant
The most commonly reported adverse events are due to the effect of atropine on muscarinic receptors and high dose on nicotinic receptors. These effects are dose-related and are usually reversible upon discontinuation of therapy.
Immune system disorders:
Nervous system disorders:
Nervousness, mental confusion, especially in the elderly. At higher doses, hallucinations, agitation, delirium.
Dilation of pupils accompanied by loss of accommodation and photophobia, decrease of lacrimal secretion, increase of intraocular pressure.
Tachycardia, palpitations, arrhythmia.
Respiratory, thoracic and mediastinal disorders:
Thickening of bronchial secretions.
Dry mouth, nausea, vomiting, constipation.
Renal and urinary disorders:
Skin and subcutaneous tissue disorders:
Dryness of the skin